Literature DB >> 33461853

Non-echoplanar diffusion weighed imaging and T1-weighted imaging for cholesteatoma mastoid extension.

Akira Baba1, Sho Kurihara2, Takeshi Fukuda3, Hideomi Yamauchi3, Satoshi Matsushima3, Koshi Ikeda3, Ryo Kurokawa4, Yoshiaki Ota5, Masahiro Takahashi2, Yuika Sakurai2, Masaomi Motegi2, Manabu Komori6, Kazuhisa Yamamoto2, Yutaka Yamamoto2, Hiromi Kojima2, Hiroya Ojiri3.   

Abstract

OBJECTIVES: A broad mastoid extension limits cholesteatoma resection via a transmeatal approach including endoscopic ear surgery. Therefore, a preoperative diagnosis of mastoid extension is a the most critical factor to determine whether to perform mastoidectomy. The purpose of this study was to assess the efficacy of non-echoplanar diffusion-weighted imaging (non-EPI DWI) and T1-weighted imaging in the evaluation of mastoid extension in cholesteatomas of the middle ear.
METHODS: Patients who underwent magnetic resonance imaging (MRI) for pretreatment evaluation before primary surgery for pars flaccida or tensa cholesteatoma, which revealed a high-signal intensity in the mastoid on T2-weighed imaging were retrospectively evaluated. Two board-certified radiologists retrospectively evaluated the extent of cholesteatomas on MRI with non-EPI DWI, non-EPI DWI- and T1-weighted axial imaging. The presence of a high signal intensity on non-EPI DWI or low or high signal intensity on T1-weighted imaging in the mastoid was evaluated. All cases were subclassified as M+ (surgically mastoid extension-positive) or M- (surgically mastoid extension-negative).
RESULTS: A total of 59 patients with middle ear cholesteatoma were evaluated. There were 37 M+ cases and 22 M- cases. High-signal intensity on non-EPI DWI exhibited a sensitivity of 0.89 and specificity of 0.82, whereas partial low-signal intensity on T1-weighted imaging exhibited a sensitivity of 0.84 and specificity of 0.91 for detecting mastoid involvement. Complete high-signal intensity on T1-weighted imaging exhibited a sensitivity of 0.73 and specificity of 0.89 for detecting non-involvement of the mastoid. The sensitivity (0.92) and specificity (0.96) of combined non-EPI DWI and T1-weighted imaging evaluation were higher than those of with non-EPI DWI or T1-weighted imaging alone. The interobserver agreement for the presence of high-signal intensity in the mastoid cavity on non-EPI DWI was very good at 0.82, that of a partial low-signal intensity area in the mastoid cavity lesions on T1-weighted imaging was good, at 0.76 and that of complete high-signal intensity in the mastoid cavity lesions on T1-weighted imaging was good, at 0.67.
CONCLUSIONS: The signal intensity on non-EPI DWI and T1-weighted imaging of the mastoid could be used to accurately assess the extent of middle ear cholesteatoma, which could facilitate surgical treatment planning.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Cholesteatoma; MRI; Mastoid; Non-echoplanar diffusion weighed imaging; T1-weighte imaging

Mesh:

Year:  2021        PMID: 33461853     DOI: 10.1016/j.anl.2021.01.010

Source DB:  PubMed          Journal:  Auris Nasus Larynx        ISSN: 0385-8146            Impact factor:   1.863


  3 in total

1.  Preoperative prediction for mastoid extension of middle ear cholesteatoma using temporal subtraction serial HRCT studies.

Authors:  Akira Baba; Ryo Kurokawa; Mariko Kurokawa; Yoshiaki Ota; Satoshi Matsushima; Takeshi Fukuda; Hideomi Yamauchi; Rui Kano; Tomokazu Shoji; Sho Kurihara; Takara Nakazawa; Yutaka Yamamoto; Hiromi Kojima; Ashok Srinivasan; Hiroya Ojiri
Journal:  Eur Radiol       Date:  2022-01-11       Impact factor: 5.315

2.  Comparison of the Utility of High-Resolution CT-DWI and T2WI-DWI Fusion Images for the Localization of Cholesteatoma.

Authors:  X Fan; C Ding; Z Liu
Journal:  AJNR Am J Neuroradiol       Date:  2022-06-02       Impact factor: 4.966

3.  Preoperative prediction by artificial intelligence for mastoid extension in pars flaccida cholesteatoma using temporal bone high-resolution computed tomography: A retrospective study.

Authors:  Masahiro Takahashi; Katsuhiko Noda; Kaname Yoshida; Keisuke Tsuchida; Ryosuke Yui; Takara Nakazawa; Sho Kurihara; Akira Baba; Masaomi Motegi; Kazuhisa Yamamoto; Yutaka Yamamoto; Hiroya Ojiri; Hiromi Kojima
Journal:  PLoS One       Date:  2022-10-03       Impact factor: 3.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.